Ionis cuts Tryngolza 2026 sales guidance, highlights Zanvastro launch and new Phase 3 wins
The company lowered Tryngolza product sales guidance to about $50 million while reporting positive Phase 3 results for sefaxersen and ulefnersen and a first Alexander disease launch.
SEC filing (2)